Relay Therapeutics (RLAY) Accumulated Expenses: 2020-2025
Historic Accumulated Expenses for Relay Therapeutics (RLAY) over the last 6 years, with Sep 2025 value amounting to $25.1 million.
- Relay Therapeutics' Accumulated Expenses fell 24.34% to $25.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $25.1 million, marking a year-over-year decrease of 24.34%. This contributed to the annual value of $21.2 million for FY2024, which is 42.62% up from last year.
- Latest data reveals that Relay Therapeutics reported Accumulated Expenses of $25.1 million as of Q3 2025, which was up 8.26% from $23.2 million recorded in Q2 2025.
- In the past 5 years, Relay Therapeutics' Accumulated Expenses registered a high of $33.2 million during Q3 2024, and its lowest value of $8.9 million during Q1 2021.
- For the 3-year period, Relay Therapeutics' Accumulated Expenses averaged around $25.0 million, with its median value being $25.1 million (2025).
- In the last 5 years, Relay Therapeutics' Accumulated Expenses skyrocketed by 135.36% in 2021 and then crashed by 34.41% in 2023.
- Relay Therapeutics' Accumulated Expenses (Quarterly) stood at $13.6 million in 2021, then spiked by 67.46% to $22.7 million in 2022, then plummeted by 34.41% to $14.9 million in 2023, then surged by 42.62% to $21.2 million in 2024, then dropped by 24.34% to $25.1 million in 2025.
- Its Accumulated Expenses stands at $25.1 million for Q3 2025, versus $23.2 million for Q2 2025 and $21.0 million for Q1 2025.